Join BullFrog AI's Exclusive Live Investor Webinar and Q&A Session on June 12
Join BullFrog AI's Exclusive Live Investor Webinar and Q&A Session on June 12
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on June 12, 2024, at 4:15 p.m. ET.
2024年5月29日马里兰盖瑟斯堡消息(环球新闻社)——BullFrog AI,Inc.(纳斯达克:BFRG;BFRGW)(“BullFrog AI”或“公司”)是一家使用人工智能(AI)和机器学习技术的科技驱动型药品研发公司,致力于成功开发药品和生物制品,非常荣幸地邀请投资者参加于2024年6月12日晚上4:15(美国东部时间)举办的网络研讨会。
To register for the free webinar, please visit:
要注册免费的网络研讨会,请访问:
The exclusive event, hosted by RedChip Companies, will feature BullFrog AI's CSO, Tom Chittenden, PhD, DPhil, PStat, and Lieber Institute for Brain Development ("LIBD") Director and CEO Daniel Weinberger, MD, who will together share insight into findings from BullFrog AI and LIBD's collaboration which successfully stratified brain expression data, offering what may turn out to be novel insights into psychiatric conditions.
这个由RedChip公司举办的独家事件将特邀BullFrog AI的CSO,Tom Chittenden博士,DPhil,PStat和Lieber大脑发育研究所(“LIBD”)的董事和首席执行官Daniel Weinberger医学博士共同分享来自BullFrog AI和LIBD的合作研究结果。他们将分享应用先进图形分析和因果AI技术分析超过2,800个脑部样本,针对精神疾病(包括精神分裂症、躁郁症、重度抑郁症和对照组)进行分类,将首次基于仅生物数据而不是行为诊断对受试者进行聚类。这种创新的方法已经发现了跨不同脑部疾病的生物差异和相似点,并为各种疾病确立了潜在的分子亚型、生物标志物和药物靶点。这些发现不仅有可能增进我们对精神疾病的认识,还为开发更具针对性和更有效的治疗方法奠定了基础,并为与制药公司达成潜在的营收共同合作打开了大门。
This collaborative effort marks a pivotal moment in psychiatric research, utilizing over 2,800 brain samples to explore schizophrenia, bipolar disorder, major depressive disorder, and control groups through advanced graph analytics and causal AI. For the first time, this partnership has enabled the clustering of subjects based on biological data alone, independent of their behavioral diagnoses. This innovative method has uncovered biological differences and similarities across various brain disorders and has identified potential molecular subtypes, biomarkers, and drug targets for individual disorders. These findings have the potential to not only enhance our understanding of psychiatric conditions but also lay the groundwork for developing more targeted, effective treatments and open the door to prospective revenue-generating partnerships with pharmaceutical companies.
这项合作标志着精神疾病研究的关键时刻,它采用先进的图形分析和因果AI技术,利用超过2,800个脑部样本对精神分裂症、躁郁症、重度抑郁症和对照组进行了探索。首次,这种合作使受试者基于仅生物数据而不是行为诊断被分类。这种创新方法已经发现了不同脑部疾病之间的生物差异和相似点,并确定了单个疾病的潜在分子亚型、生物标志物和药物靶点。这些发现不仅有可能增进我们对精神疾病的认识,还为开发更具针对性和更有效的治疗方法奠定了基础,并为与制药公司达成潜在的营收共同合作打开了大门。
Questions can be pre-submitted to BFRG@redchip.com or online during the live event.
问题可以在现场研讨会期间在线提交或预先发送到BFRG@redchip.com。
About BullFrog AI
关于BullFrog AI
BullFrog AI is a technology-enabled drug development company using Artificial Intelligence and machine learning to enable the successful development of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP artificial intelligence platform to create and analyze networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.
BullFrog AI是一家使用人工智能和机器学习技术的科技驱动型药品研发公司,致力于成功开发药品和生物制品。通过与领先的研究机构的合作,BullFrog AI是AI驱动药品研发的先锋,使用其专有的bfLEAP人工智能平台创建和分析从早期发现到后期临床试验的生物、临床和真实世界数据网络。BullFrog AI正打算在开发的几个重要阶段采用bfLEAP,以旨在在治疗法开发的各个关键阶段简化数据分析,通过减少新疗法的失败率来降低总体开发成本。
For more information visit BullFrog AI at:
有关BullFrog AI的更多信息,请访问:
Website:
网站:
LinkedIn:
领英:
Safe Harbor Statement
Safe Harbor声明
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
本新闻稿包含前瞻性陈述。我们基于当前对我们的信息,展望和预测,作出这些前瞻性的陈述。此类前瞻性陈述涉及未来事件或我们的未来表现,包括:我们的财务表现和展望;我们收入和利润的增长;以及我们的商业前景和机会。您可以通过未采用历史性语言的前瞻性语言来识别其。通过考虑各种因素来评估这些前瞻性声明,包括:我们改变公司方向的能力;我们跟上新技术和不断变化的市场需求的能力;以及我们所处市场的竞争环境。这些和其他因素可能导致我们的实际结果与任何前瞻性声明不符,前瞻性声明仅为预测。在本新闻稿中讨论的前瞻性事件以及我们或我们的代表不时发表的其他声明可能不会发生,实际事件和结果会有所不同,并且不受关于我们的风险、不确定性和假设的影响。我们没有义务公开更新或修订任何前瞻性声明,不论是由于不确定性和假设,还是由于我们或我们的代表不断发表的前瞻性事件可能不会发生。
Contact:
联系方式:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com